On January 8, 2026, Imeik Technology Development Co., Ltd. successfully obtained the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for the Botulinum Toxin Type A for Injection. This product is exclusively distributed by Imeik in China (including the Hong Kong Special Administrative Region and the Macao Special Administrative Region) and is manufactured by South Korea's Huons BioPharma Co., Ltd.

The approval for the research and development of Botulinum Toxin Type A for Injection for registration purposes has further advanced the strategic layout of Imeik’s product portfolio, holding significant importance during this period of rapid industry development. To date, Imeik has established a diverse product line that includes hyaluronic acid-based dermal fillers, polylactic acid-based dermal fillers, polydioxanone-based facial thread implants, and neuro-modulating botulinum toxin-based biologics. This continuously meets the growing public demand for a better quality of life.